The prevalence of diabetes in China has increased rapidly from 0.67% in 1980 to 10.4% in
2013, with the aging of the population and westernization of lifestyle. Since its foundation in …

随着经济高速发展和工业化进程的加速, 生活方式的改变和老龄化进程的加速,
使我国糖尿病的患病率正呈快速上升的趋势, 成为继心脑血管疾病, 肿瘤之后另一个严重危害 …

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that enhances glucose-stimulated
insulin secretion and exerts direct and indirect actions on the cardiovascular system. GLP-1 …

The past 30 years have witnessed significant increases in the prevalence of type 2 diabetes
mellitus (T2DM) in China. A 1980 epidemiological survey that included 30 000 people from …

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4)
inhibitors represent 2 distinct classes of incretin-based therapies used for the treatment of …

Objectives To synthesise current evidence for the effects of exenatide and liraglutide on
heart rate, blood pressure and body weight. Design Meta-analysis of available data from …

Objective To investigate the risk of pancreatitis associated with the use of incretin-based
treatments in patients with type 2 diabetes mellitus. Design Systematic review and meta …

Background Glucagon‐like peptide analogues are a new class of drugs used in the
treatment of type 2 diabetes that mimic the endogenous hormone glucagon‐like peptide 1 …

Liraglutide is an acylated glucagon-like peptide-1 analogue with 97% amino acid homology
with native glucagon-like peptide-1 and greatly protracted action. It is widely used for the …

BACKGROUND: Considerable clinical data on the treatment of type 2 diabetes with incretin-
based therapies (glucagon-like peptide 1 receptor agonists [GLP-1RAs] and dipeptidyl …